Compare up to 40 stocks
Compared Stocks: 1 / 40
| Name | Sector | Price | Volume | Market Cap | P/E Ratio | Dividend Yield | Analyst Consensus | Analyst Price Target | Smart Score | Leveraged ETF | Article | Follow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
 SNOA | Healthcare | $1.09 | 94.78K | $6.28M | -1.27 | ― | ― |
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SNOA | Sonoma Pharmaceuticals | 1.09 | -2.11 | -65.99% |
| Name | Price | % Change | |
|---|---|---|---|
| SNOA | $1.09 | -65.99% |
16:34 EST Sonoma Pharmaceuticals (SNOA) files $46.65M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks
An announcement from Sonoma Pharmaceuticals ( ($SNOA) ) is now available. On October 6, 2026, Sonoma Pharmaceuticals’ board approved a new Section 382 rights agreement with Computershare Inc., effective immediately
Sonoma Pharmaceuticals ( ($SNOA) ) has issued an announcement. Sonoma Pharmaceuticals held its annual meeting of stockholders on September 16, 2026, with 2,082,799 shares of common stock present or represented
Sonoma Pharmaceuticals ( ($SNOA) ) has shared an announcement. On August 19, 2026, Sonoma Pharmaceuticals, Inc. convened an adjourned special meeting of stockholders that had been called pursuant to a
Reports revenue $6.4M vs. $4.02M last year. “Our first quarter results demonstrate that Sonoma has reached an important inflection point,” said Amy Trombly, CEO of Sonoma. “We delivered record quarterly
Sonoma Pharmaceuticals (SNOA) has received a new 510(k) clearance from the U.S. Food and Drug Administration for its Microdacyn Wound Irrigation Solution, including expanded claims, clearance for multiple use, and
Sonoma Pharmaceuticals ( ($SNOA) ) has shared an announcement. On September 26, 2025, Sonoma Pharmaceuticals, Inc. entered into an at-the-market issuance sales agreement with Ladenburg Thalmann & Co. to sell
Sonoma Pharmaceuticals ( ($SNOA) ) just unveiled an announcement. On April 24, 2026, Sonoma Pharmaceuticals, Inc., a Nasdaq-listed HOCl-focused healthcare company, entered into an underwriting agreement with Dawson James Securities
Sonoma Pharmaceuticals (SNOA) announced the pricing of its public offering made on a firm commitment basis with gross proceeds to the Company expected to be approximately $4M, before deducting fees
Dawson James Securities is acting as manager. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >>
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| SNOA | Feb 16, 2027TBA | $6.28M | ― | ― | 0.03 | -1.27 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.
